The past few months have been "dodgy" for the SIPP, and this week one of my shareholdings has fallen off the cliff!
The current holdings are as follows:
Investment Trusts
Fidelity Asian Values IT (FAS): 1337 shares
JPMorgan Emerging Markets IT (JMG): 600 shares
Jupiter US Smaller Co IT (JUS): 500 shares
Individual Companies
Booker Group (BOK): 4500 shares
GlaxoSmithKline (GSK): 620 shares
International Personal Finance (IPF): 2000 shares
Optimal Payments (OPAY): 3500 shares
Scapa Group (SCPA): 2080 shares
Segro (SGRO): 1140 shares
Telit Communications (TCM): 850 shares
XChanging (XCH): 1740 shares
Cash: £16,315.46
Current Value (15th December 2014) = £72,500 (approx)
As I started the year with the SIPP at a value of £70,400 and I've added £3,600 to it in direct monthly contributions AND £1,295.88 in dividends, the performance this year has been disappointing.
The portfolio has taken a few big hits in recent weeks, the worst of them being in the past week with OPAY dropping to under 320 today (from a high of 550 in mid-September). I just don't know what the issues are with this share as the 4 broker forecasts are all suggesting a value greater than 600. Add to that the comments of Joel Leonoff, President & CEO on 17th November 2014: “We are finishing 2014 stronger and more diversified and, as a result, increasingly confident in the outlook for the accretive organic and inorganic growth opportunities available to us."
IPF is another shareholding in the SIPP that has been having a poor time on the markets with no obvious reason to explain it. The share value has slumped from 630 in early-June to under 440 now - yet the company is expecting to declare full year results showing increased profits up 20% on last year. The company looks stronger now than it did 6-months ago when the share price was 50% greater.
These companies both look strong: they both hold unique positions in their relative fields and I can only think that it is just a matter of time before the markets recognise this and the share price is driven higher.
No comments:
Post a Comment